KURA ONCOLOGY, INC. Interest and Debt Expense
KURA ONCOLOGY, INC. (KURA) reported Interest and Debt Expense of $414.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestAndDebtExpense · last filed 2021-11-04
- KURA ONCOLOGY, INC. interest and debt expense for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- KURA ONCOLOGY, INC. interest and debt expense for the quarter ending 2021-06-30 was $306.00K, a 112.50% increase year-over-year.
- KURA ONCOLOGY, INC. interest and debt expense for the quarter ending 2020-09-30 was $146.00K.
- KURA ONCOLOGY, INC. interest and debt expense for the quarter ending 2020-06-30 was $144.00K.
| Period end | Interest and Debt Expense 3 month | Interest and Debt Expense 6 month | Interest and Debt Expense 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $306.00K derived: sum of 2 quarters · filed 2021-11-04 | $414.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $306.00K 10-Q · filed 2021-08-05 | $414.00K 10-Q · filed 2021-08-05 | |
| 2020-09-30 | $146.00K 10-Q · filed 2021-11-04 | $290.00K derived: sum of 2 quarters · filed 2021-11-04 | $434.00K 10-Q · filed 2021-11-04 |
| 2020-06-30 | $144.00K 10-Q · filed 2021-08-05 | $288.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |